🚀 VC round data is live in beta, check it out!
Proteomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Proteomics and similar public comparables like Carelabs, Data Horizon, Genoway, Biohit and more.
Proteomics Overview
About Proteomics
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Founded
2014
HQ
Employees
N/A
Website
Financials (LTM)
EV
$32M
Proteomics Financials
Proteomics reported last 12-month revenue of $2M and negative EBITDA of ($5M).
In the same LTM period, Proteomics generated $2M in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).
Revenue (LTM)
Proteomics P&L
In the most recent fiscal year, Proteomics reported revenue of $2M and EBITDA of ($5M).
Proteomics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | $673K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | (214%) | XXX | (214%) | XXX | XXX | XXX |
| EBIT Margin | (231%) | XXX | (231%) | XXX | XXX | XXX |
| Net Profit | ($5M) | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | (232%) | XXX | (232%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Proteomics Stock Performance
Proteomics has current market cap of $39M, and enterprise value of $32M.
Market Cap Evolution
Proteomics' stock price is $0.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $39M | (0.9%) | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProteomics Valuation Multiples
Proteomics trades at 14.0x EV/Revenue multiple, and (6.5x) EV/EBITDA.
EV / Revenue (LTM)
Proteomics Financial Valuation Multiples
As of March 7, 2026, Proteomics has market cap of $39M and EV of $32M.
Equity research analysts estimate Proteomics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Proteomics has a P/E ratio of (7.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $39M | XXX | $39M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV/Revenue | 14.0x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBITDA | (6.5x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/EBIT | (6.1x) | XXX | (6.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 14.0x | XXX | 47.3x | XXX | XXX | XXX |
| P/E | (7.4x) | XXX | (7.4x) | XXX | XXX | XXX |
| EV/FCF | (7.2x) | XXX | (7.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Proteomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Proteomics Margins & Growth Rates
Proteomics' revenue in the last fiscal year grew by 4%.
Proteomics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | (214%) | XXX | (214%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 190% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 357% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Proteomics Public Comps
See public comps and valuation multiples for other Life Sciences Tools and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Carelabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Data Horizon | XXX | XXX | XXX | XXX | XXX | XXX |
| Genoway | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Proteomics M&A Activity
Proteomics acquired XXX companies to date.
Last acquisition by Proteomics was on XXXXXXXX, XXXXX. Proteomics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Proteomics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProteomics Investment Activity
Proteomics invested in XXX companies to date.
Proteomics made its latest investment on XXXXXXXX, XXXXX. Proteomics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Proteomics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Proteomics
| When was Proteomics founded? | Proteomics was founded in 2014. |
| Where is Proteomics headquartered? | Proteomics is headquartered in Australia. |
| Is Proteomics publicly listed? | Yes, Proteomics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Proteomics? | Proteomics trades under PIQ ticker. |
| When did Proteomics go public? | Proteomics went public in 2015. |
| Who are competitors of Proteomics? | Proteomics main competitors are Carelabs, Data Horizon, Genoway, Biohit. |
| What is the current market cap of Proteomics? | Proteomics' current market cap is $39M. |
| What is the current revenue of Proteomics? | Proteomics' last 12 months revenue is $2M. |
| What is the current EV/Revenue multiple of Proteomics? | Current revenue multiple of Proteomics is 14.0x. |
| Is Proteomics profitable? | No, Proteomics is not profitable. |
| What is the current EBITDA of Proteomics? | Proteomics has negative EBITDA and is not profitable. |
| What is Proteomics' EBITDA margin? | Proteomics' last 12 months EBITDA margin is (214%). |
| What is the current EV/EBITDA multiple of Proteomics? | Current EBITDA multiple of Proteomics is (6.5x). |
| What is the current FCF of Proteomics? | Proteomics' last 12 months FCF is ($4M). |
| What is Proteomics' FCF margin? | Proteomics' last 12 months FCF margin is (194%). |
| What is the current EV/FCF multiple of Proteomics? | Current FCF multiple of Proteomics is (7.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.